LT3 Stock Overview
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
AxoGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.35 |
| 52 Week High | US$9.75 |
| 52 Week Low | US$3.26 |
| Beta | 1.02 |
| 1 Month Change | -4.51% |
| 3 Month Change | -23.49% |
| 1 Year Change | -22.56% |
| 3 Year Change | -57.67% |
| 5 Year Change | -66.83% |
| Change since IPO | -17.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| LT3 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -1.6% | 1.7% | 1.7% |
| 1Y | -22.6% | -7.7% | 2.3% |
Return vs Industry: LT3 underperformed the German Medical Equipment industry which returned -9.5% over the past year.
Return vs Market: LT3 underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| LT3 volatility | |
|---|---|
| LT3 Average Weekly Movement | 7.2% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LT3's share price has been volatile over the past 3 months.
Volatility Over Time: LT3's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 427 | Karen Zaderej | www.axogeninc.com |
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.
AxoGen, Inc. Fundamentals Summary
| LT3 fundamental statistics | |
|---|---|
| Market cap | €284.64m |
| Earnings (TTM) | -€20.29m |
| Revenue (TTM) | €148.58m |
1.9x
P/S Ratio-13.8x
P/E RatioIs LT3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LT3 income statement (TTM) | |
|---|---|
| Revenue | US$159.01m |
| Cost of Revenue | US$31.14m |
| Gross Profit | US$127.87m |
| Other Expenses | US$149.59m |
| Earnings | -US$21.72m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 80.42% |
| Net Profit Margin | -13.66% |
| Debt/Equity Ratio | 51.8% |
How did LT3 perform over the long term?
See historical performance and comparison